Advertisement

Current Hypertension Reports

, 21:70 | Cite as

Blood Pressure and Statin Effects on Cognition: a Review

  • Mia YangEmail author
  • Jeff Williamson
Secondary Hypertension: Nervous System Mechanisms (M Wyss, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Secondary Hypertension: Nervous System Mechanisms

Abstract

Purpose of Review

This is a review of available data on the effects of blood pressure and statins on cognition.

Recent Findings

Recent randomized clinical trials have shown that intensive control of systolic blood pressure in older adults prevented the development of mild cognitive impairment (MCI) and the combined effects of MCI and probable dementia. Previous randomized clinical trials have suggested that statin use may prevent a decline in cognition; however, no randomized clinical trials have clearly shown evidence of statin’s either positive or negative effect on cognition.

Summary

Continued follow-up of SPRINT-MIND participants is crucial to evaluate the long-term effects of intensive systolic blood pressure control on the prevention of cognitive decline. A well-conducted and adequately powered randomized control trial is needed to evaluate the effect of statins on cognition, especially for primary prevention of the cognitive decline in aging.

Keywords

Blood pressure Statin Hypertension Cognition Cognitive impairment Dementia 

Notes

Compliance with Ethical Standards

Conflict of Interest

Dr. Williamson reports grants from the National Institutes of Health, during the conduct of the study; Dr. Yang declares no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    2019 Alzheimer’s disease facts and figures includes a special report on Alzheimer’s detection in the primary care setting: connecting patients and physicians. https://alz.org/media/Documents/alzheimers-facts-and-figures-2019-r.pdf. Accessed April 2, 2019.
  2. 2.
    Bos D, Vernooij MW, Ee R, et al. Atherosclerotic calcification is related to a higher risk of dementia and cognitive decline.  https://doi.org/10.1016/j.jalz.2014.05.1758 CrossRefGoogle Scholar
  3. 3.
    Iadecola C, Yaffe K, Biller J, et al. Impact of hypertension on cognitive function: a scientific statement from the American Heart Association. Hypertens (Dallas, Tex 1979). 2016;68(6):e67–94.  https://doi.org/10.1161/HYP.0000000000000053.CrossRefGoogle Scholar
  4. 4.
    Mossello E, Pieraccioli M, Nesti N, et al. Effects of low blood pressure in cognitively impaired elderly patients treated with antihypertensive drugs. JAMA Intern Med. 2015;175(4):578.  https://doi.org/10.1001/jamainternmed.2014.8164.CrossRefPubMedGoogle Scholar
  5. 5.
    Sabayan B, Westendorp RGJ. Blood pressure control and cognitive impairment—why low is not always better. JAMA Intern Med. 2015;175(4):586.  https://doi.org/10.1001/jamainternmed.2014.8202.CrossRefPubMedGoogle Scholar
  6. 6.
    Verghese J, Lipton RB, Hall CB, Kuslansky G, Katz MJ. Low blood pressure and the risk of dementia in very old individuals. Neurology. 2003;15(61):1667–72.CrossRefGoogle Scholar
  7. 7.
    Qiu C, Winblad B, Fratiglioni L. Low diastolic pressure and risk of dementia in very old people: a longitudinal study. Dement Geriatr Cogn Disord. 2009;28:213–9.  https://doi.org/10.1159/000236913.CrossRefPubMedGoogle Scholar
  8. 8.
    Saper CB. How low can you go? Ann Neurol. 2015;78(5):665–6.  https://doi.org/10.1002/ana.24530.CrossRefPubMedGoogle Scholar
  9. 9.
    O’Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney cause and logic of therapy epidemiological studies and clinical trials. Hypertension. 2005;46:200–4.  https://doi.org/10.1161/01.HYP.0000168052.00426.65.CrossRefPubMedGoogle Scholar
  10. 10.
    •• Williamson JD, Pajewski NM, Auchus AP, et al. Effect of Intensive vs standard blood pressure control on probable dementia. JAMA. 2019;321(6):553.  https://doi.org/10.1001/jama.2018.21442 With a median of 5.5 years of follow-up, SPRINT-MIND demonstrated a positive effect of the mean 3.3 years of intensive blood pressure control for lowering rates of mild cognitive impairment (MCI). Results were not conclusive for probable dementia. The estimated reduction in risk for probable dementia was in the same direction and of the same magnitude as for MCI (19%, p= 0.008), but the hazard ratio estimate for probable dementia was not statistically significant (17%, p= 0.10). Consistent with this conclusion, the composite outcome of MCI or PD demonstrated a 15% reduction (HR of 0.85, p= 0.01). CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Rouch L, Cestac P, Hanon O, et al. Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms. CNS Drugs. 2015;29(2):113–30.  https://doi.org/10.1007/s40263-015-0230-6.CrossRefPubMedGoogle Scholar
  12. 12.
    Yaffe K, Vittinghoff E, Pletcher MJ, et al. Early adult to midlife cardiovascular risk factors and cognitive function. Circulation. 2014;129(15):1560–7.  https://doi.org/10.1161/CIRCULATIONAHA.113.004798.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    • Gottesman RF, Albert MS, Alonso A, et al. Associations between midlife vascular risk factors and 25-year incident dementia in the Atherosclerosis Risk in Communities (ARIC) Cohort. JAMA Neurol. 2017;74(10):1246.  https://doi.org/10.1001/JAMANEUROL.2017.1658 Midlife vascular risk factors are associated with increased risk of dementia in black and white ARIC Study participants. Vascular risk factors include the following: midlife smoking (HR, 1.41; 95% CI, 1.23–1.61), diabetes (HR, 1.77; 95% CI, 1.53–2.04), prehypertension (HR, 1.31; 95% CI, 1.14–1.51), and hypertension (HR, 1.39; 95% CI, 1.22–1.59). The HR for dementia for diabetes was almost as high as that for APOE ε4 genotype. CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Elias MF, Torres RV, Davey A. Clinical trials of blood pressure lowering and antihypertensive medication: is cognitive measurement state-of-the-art? Am J Hypertens. 2018;31(6):631–42.  https://doi.org/10.1093/ajh/hpy033.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Williamson JD, Launer LJ, Bryan RN, et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Intern Med. 2014;174(3):324–33.  https://doi.org/10.1001/jamainternmed.2013.13656.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    SPRINT Research Group TSR, Wright JT, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.  https://doi.org/10.1056/NEJMoa1511939.CrossRefGoogle Scholar
  17. 17.
    Ambrosius WT, Sink KM, Foy C, et al. The design and rationale of a multi-center clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials. 2014;11(5):532–46.  https://doi.org/10.1177/1740774514537404.CrossRefPubMedGoogle Scholar
  18. 18.
    Bernard MA, Clayton JA, Lauer MS. Inclusion across the lifespan. JAMA. 2018;320(15):1535.  https://doi.org/10.1001/jama.2018.12368.CrossRefPubMedGoogle Scholar
  19. 19.
    Singh S, Zieman S, Go AS, et al. Statins for primary prevention in older adults-moving toward evidence-based decision-making. J Am Geriatr Soc. 2018;66(11):2188–96.  https://doi.org/10.1111/jgs.15449.CrossRefPubMedGoogle Scholar
  20. 20.
    Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA Guideline on the assessment of cardiovascular risk. Circulation. 2014;129(25 suppl 2):49–73.  https://doi.org/10.1161/01.cir.0000437741.48606.98.CrossRefGoogle Scholar
  21. 21.
    Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113:791–8.  https://doi.org/10.1161/CIRCULATIONAHA.105.548206.CrossRefPubMedGoogle Scholar
  22. 22.
    Bonow RO. Primary prevention of cardiovascular disease: a call to action. Circulation. 2002;106(25):3140–1.  https://doi.org/10.1161/01.CIR.0000048067.86569.E1.CrossRefPubMedGoogle Scholar
  23. 23.
    Johansen ME, Green LA. Statin use in very elderly individuals , 1999–2012 Rates of kidney transplantation from living and deceased donors for Blacks and Whites in the United States , 1998 to 2011. JAMA Intern Med. 2015;175(10):20–1.  https://doi.org/10.1001/jamainternmed.2015.4302.Author.CrossRefGoogle Scholar
  24. 24.
    LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425–35.  https://doi.org/10.1056/NEJMoa050461.CrossRefPubMedGoogle Scholar
  25. 25.
    Odden MC, Pletcher MJ, Coxson PG, et al. The population impact and cost-effectiveness of statins for primary prevention in adults 75 and older in the United States. Ann Intern Med. 2015;162(8):533–41.  https://doi.org/10.7326/M14-1430.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Smith EE. Clinical presentations and epidemiology of vascular dementia. Clin Sci. 2017;131(11):1059–68.  https://doi.org/10.1042/CS20160607.CrossRefPubMedGoogle Scholar
  27. 27.
    Snyder HM, Corriveau RA, Craft S, et al. Vascular contributions to cognitive impairment and dementia including Alzheimer’s disease HHS public access. Alzheimers Dement. 2015;11(6):710–7.  https://doi.org/10.1016/j.jalz.2014.10.008.CrossRefPubMedGoogle Scholar
  28. 28.
    Petersen RC, Lopez O, Armstrong MJ, et al. Approved by the Guideline Development, Dissemination, and Implementation Subcommittee on. Neurol ®. 2018;90:126–35.  https://doi.org/10.1212/WNL.0000000000004826.CrossRefGoogle Scholar
  29. 29.
    Aliberti MJR, Cenzer IS, Smith AK, et al. Risk assessment of adverse outcomes for older adults: the need to include both physical and cognitive elements. J Am Geriatr Soc. 2019;67(3):477–83.  https://doi.org/10.1111/jgs.15683.CrossRefPubMedGoogle Scholar
  30. 30.
    Kivipelto M, Helkala E-L, Laakso MP, et al. Apolipoprotein E ϵ4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med. 2002;137(3):149.  https://doi.org/10.7326/0003-4819-137-3-200208060-00006.CrossRefPubMedGoogle Scholar
  31. 31.
    • Kuller LH, Lopez OL, Becker JT, et al. Risk of dementia and death in the long-term follow-up of the Pittsburgh Cardiovascular Health STudy-Cognition Study. Alzheimer’s Dement. 2016;12(2):170–83.  https://doi.org/10.1016/j.jalz.2015.08.165 More participants with normal cognition had coronary artery calcium scores < 10 compared to those with dementia or died. CrossRefGoogle Scholar
  32. 32.
    • Kuller LH, Lopez OL, Mackey RH, et al. Subclinical cardiovascular disease and death, dementia, and coronary heart disease in individuals age 80+. J Am Coll Cardiol. 2016;67(9):1013–22.  https://doi.org/10.1016/j.jacc.2015.12.034 Subclinical measure of cardiovascular disease, CAC, or coronary artery calcium is associated with the incidence of dementia in individuals age 80+. White women with low CAC scores had significantly decreased incidence of dementia. CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Swiger KJ, Manalac RJ, Blumenthal RS, Blaha MJ, Martin SS. Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc. 2013;88(11):1213–21.  https://doi.org/10.1016/j.mayocp.2013.07.013.CrossRefPubMedGoogle Scholar
  34. 34.
    Tan ZS, Seshadri S, Beiser A, Wilson Peter WF, Kiel DP, Tocco M, et al. Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. JAMA Intern Med. 2003;163:1053–7.CrossRefGoogle Scholar
  35. 35.
    Mainous A. G; Eschenbach, Stephanie L; Wells, Brian J; Everett, Charles J; Gill JM. Cholesterol, transferrin saturation, and the development of dementia and Alzheimer’s disease: results from an 18-year population-based cohort. Fam Med. 2005;37(1):36–42 https://fammedarchives.blob.core.windows.net/imagesandpdfs/fmhub/fm2005/January/Arch36.pdf.PubMedGoogle Scholar
  36. 36.
    Hayden KM, Zandi PP, Lyketsos CG, et al. Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County Study. Alzheimer Dis Assoc Disord. 2006;20(2):93–100.  https://doi.org/10.1097/01.wad.0000213814.43047.86.CrossRefPubMedGoogle Scholar
  37. 37.
    Solomon A, Sippola R, Soininen H, et al. Treatment and prevention lipid-lowering treatment is related to decreased risk of dementia: a population-based study (FINRISK). Neurodegener Dis. 2010;7:180–2.  https://doi.org/10.1159/000295659.CrossRefPubMedGoogle Scholar
  38. 38.
    Solomon A, Kåreholt I, Ngandu T, et al. Serum total cholesterol, statins and cognition in non-demented elderly. Neurobiol Aging. 2009;30:1006–9.  https://doi.org/10.1016/j.neurobiolaging.2007.09.012.CrossRefPubMedGoogle Scholar
  39. 39.
    Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA. Midlife serum cholesterol and increased risk of Alzheimer’s and vascular dementia three decades later. Dement Geriatr Cogn Disord. 2009;28:75–80.  https://doi.org/10.1159/000231980.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Reitz C, Tang M-X, Schupf N, et al. Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. Arch Neurol. 2010;67(12):1491–7.  https://doi.org/10.1001/archneurol.2010.297.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Mielke MM, Zandi PP, Sjogren M, et al. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology. 2005;64(10):1689–95.  https://doi.org/10.1212/01.WNL.0000161870.78572.A5.CrossRefPubMedGoogle Scholar
  42. 42.
    Reitz C, Tang M-X, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol. 2004;61(5):705–14.  https://doi.org/10.1001/archneur.61.5.705.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Gouw AA, Van Der Flier WM, Fazekas F, et al. Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the leukoaraiosis and disability study. Stroke. 2008;39(5):1414–20.  https://doi.org/10.1161/STROKEAHA.107.498535.CrossRefPubMedGoogle Scholar
  44. 44.
    Longstreth WT, Arnold AM, Beauchamp NJ, et al. Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the cardiovascular health study. Stroke. 2005;36(1):56–61.  https://doi.org/10.1161/01.STR.0000149625.99732.69.CrossRefPubMedGoogle Scholar
  45. 45.
    Van Dijk EJ, Prins ND, Vrooman HA, Hofman A, Koudstaal PJ, Breteler MMB. Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences Rotterdam Scan Study. Stroke. 2008:2712–9.  https://doi.org/10.1161/STROKEAHA.107.513176.CrossRefGoogle Scholar
  46. 46.
    Sturgeon JD, Folsom AR, Longstreth WT, Shahar E, Rosamond WD, Cushman M. Risk factors for intracerebral hemorrhage in a pooled prospective study. Stroke. 2007;38(10):2718–25.  https://doi.org/10.1161/STROKEAHA.107.487090.CrossRefPubMedGoogle Scholar
  47. 47.
    Bonaventure A, Kurth T, Pico F, et al. Triglycerides and risk of hemorrhagic stroke vs. ischemic vascular events: the Three-City Study. Atherosclerosis. 2010;210:243–8.  https://doi.org/10.1016/j.atherosclerosis.2009.10.043.CrossRefPubMedGoogle Scholar
  48. 48.
    Wieberdink RG, Poels MMF, Vernooij MW, et al. Serum lipid levels and the risk of intracerebral hemorrhage: the Rotterdam study. Arterioscler Thromb Vasc Biol. 2011;31(12):2982–9.  https://doi.org/10.1161/ATVBAHA.111.234948.CrossRefPubMedGoogle Scholar
  49. 49.
    MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. Lancet. 2002;360(9326):7–22.  https://doi.org/10.1016/S0140-6736(02)09327-3
  50. 50.
    LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. Vol 352.; 2005. www.nejm. Accessed May 14, 2019.
  51. 51.
    Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8(5):453–63.  https://doi.org/10.1016/S1474-4422(09)70058-4.CrossRefPubMedGoogle Scholar
  52. 52.
    Cholesterol Treatment Trialists’ Collaboration CTT. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet (London, England). 2019;393(10170):407–15.  https://doi.org/10.1016/S0140-6736(18)31942-1.CrossRefGoogle Scholar
  53. 53.
    Gorelick P, Black E, DeCarli C, et al. Vascular contributions to cognitive impairment and dementia: Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, Council on Cardiovascular Surgery and Anesthesia. Stroke. 2011;42(9):2672–713.  https://doi.org/10.1161/STR.0b013e3182299496.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Trompet S, Peter AE, Ae V, et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol. 2010;257:85–90.  https://doi.org/10.1007/s00415-009-5271-7.CrossRefPubMedGoogle Scholar
  55. 55.
    Fu JH, Mok V, Lam W, et al. Effects of statins on progression of subclinical brain infarct. Cerebrovasc Dis. 2010;30(1):51–6.  https://doi.org/10.1159/000313614.CrossRefPubMedGoogle Scholar
  56. 56.
    Ten Dam VH, Van Den Heuvel DMJ, Van Buchem MA, et al. Effect of pravastatin on cerebral infarcts and white matter lesions. Neurology. 2005;64(10):1807–9.  https://doi.org/10.1212/01.WNL.0000161844.00797.73.CrossRefPubMedGoogle Scholar
  57. 57.
    • Bath PM, Scutt P, Blackburn DJ, et al. Intensive versus guideline blood pressure and lipid lowering in patients with previous stroke: main results from the pilot “Prevention of Decline in Cognition after Stroke Trial” (PODCAST) randomised controlled trial. PLoS One. 2017.  https://doi.org/10.1371/journal.pone.0164608 In patients with recent stroke and normal cognition, intensive blood pressure and lipid lowering were feasible and safe but did not alter cognition as measured by Addenbrooke’s Cognitive Examination-Revised (ACE-R) over two years. Intensive lipid lowering therapy was associated with some secondary outcomes such as trail making A, modified Rankin Scale, and Euro-Qol Visual Analogue Scale, suggesting a need for further clinical trial. CrossRefGoogle Scholar
  58. 58.
    Lütjohann D, Papassotiropoulos A, Björkhem I, et al. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. Supplementary key words brain cholesterol • Apolipoprotein E • Cell Membrane • Isotope Dilution-Mass Spectrometry • Hippocampus • Senile Plaques • Depression • Blood-Brain Barrier. Vol 41.; 2000. www.jlr.org. Accessed May 23, 2019.
  59. 59.
    Dietschy JMTS. Cholesterol metabolism in the brain. Curr Opin Lipidol. 2001;12(2):105–12.  https://doi.org/10.1007/BF02531730.CrossRefPubMedGoogle Scholar
  60. 60.
    Strittmatter WJ, Weisgraber KH, Huang DY, et al. Binding of human apolipoprotein e to synthetic amyloid ,B peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Vol 90.; 1993. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC47295/pdf/pnas01474-0198.pdf. Accessed May 23, 2019.
  61. 61.
    K. C, GK. W, S. L. APOE epsilon 4 influences the pathological phenotype of Alzheimer’s disease by favouring cerebrovascular over parenchymal accumulation of A beta protein. Neuropathol Appl Neurobiol. 2003;29(3 PG-231-8):231–238. NS -.CrossRefGoogle Scholar
  62. 62.
    Thal Rudolf D, Capetillo-Zarate E, Shultz C, et al. Apolipoprotein E co-localizes with newly formed amyloid b-protein (Ab) deposits lacking immunoreactivity against N-terminal epitopes of Ab in a genotype-dependent manner. Acta Neuropathol. 2005;110:459–71.  https://doi.org/10.1007/s00401-005-1053-1.CrossRefGoogle Scholar
  63. 63.
    Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer ’s disease. Science (80- ). 2002;297(5580):353–357.CrossRefGoogle Scholar
  64. 64.
    Neu SC, Pa J, Kukull W, et al. Apolipoprotein E genotype and sex risk factors for Alzheimer’s disease HHS Public Access. 2017;74(10):1178–1189. doi: https://doi.org/10.1001/jamaneurol.2017.2188 CrossRefGoogle Scholar
  65. 65.
    Phillips MC. Apolipoprotein e isoforms and lipoprotein metabolism. IUBMB Life. 2014;66(9):616–23.  https://doi.org/10.1002/iub.1314.CrossRefPubMedGoogle Scholar
  66. 66.
    Yang D, Knight RA, Han Y, et al. Statins protect the blood brain barrier acutely after experimental intracerebral hemorrhage. J Behav Brain Sci. 2013;3(1):100–6 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583226/pdf/nihms434278.pdf. Accessed May 23, 2019.CrossRefGoogle Scholar
  67. 67.
    Miida T, Hirayama S, Nakamura Y. Cholesterol-independent effects of statins and new therapeutic targets: ischemic stroke and dementia. J Atheroscler Thromb. 2011;11(5):253–64.  https://doi.org/10.5551/jat.11.253.CrossRefGoogle Scholar
  68. 68.
    Fan J, Donkin J, Wellington C. Greasing the wheels of Aβ clearance in Alzheimer’s disease: the role of lipids and apolipoprotein e. BioFactors. 2009;35(3):239–48.  https://doi.org/10.1002/biof.37.CrossRefPubMedGoogle Scholar
  69. 69.
    Reiss AB, Siller KA, Rahman MM, Chan ESL, Ghiso J, De Leon MJ. Cholesterol in neurologic disorders of the elderly: stroke and Alzheimer’s disease. Neurobiol Aging. 2004;25:977–89.  https://doi.org/10.1016/j.neurobiolaging.2003.11.009.CrossRefPubMedGoogle Scholar
  70. 70.
    • Mefford MT, Rosenson RS, Cushman M, et al. PCSK9 variants, LDL-cholesterol, and neurocognitive impairment: the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. 2Circulation. 2018;137(12):1260–9.  https://doi.org/10.1161/CIRCULATIONAHA.117.029785 PCSK9 loss-of-function (LOF) variants result in lifelong low LDL-C. The REGARDS investigators investigated the association between PCSK9 LOF variants and neurocognitive impairment among African-American participants with the variants compared with those without the variants. Low PCSK9 levels and low LDL-C were not associated with neurocognitive effects in African Americans. CrossRefGoogle Scholar
  71. 71.
    • Giugliano RP, Mach F, Zavitz K, et al. Cognitive function in a randomized trial of evolocumab. N Engl J Med. 2017;377(7):633–43.  https://doi.org/10.1056/NEJMoa1701131 Evolocumab is a PCSK9 inhibitor that has shown to reduce rate of cardiovascular events among patients with established cardiovascular disease. In a subgroup of patients from randomized, placebo-controlled trial of evolocumab added to statin therapy, cognitive function was prospectively assessed in 1204 patients followed for a median of 19 months. There were no significant between-group differences in evolocumab and placebo groups. CrossRefPubMedGoogle Scholar
  72. 72.
    FDA. FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-important-safety-label-changes-cholesterol-lowering-statin-drugs. Published 2016.
  73. 73.
    Bettermann K, Arnold AM, Williamson J, et al. Statins, risk of dementia, and cognitive function: secondary analysis of the Ginkgo Evaluation of Memory Study. J Stroke Cerebrovasc Dis. 2012;21(6):436–44.  https://doi.org/10.1016/j.jstrokecerebrovasdis.2010.11.002.CrossRefPubMedGoogle Scholar
  74. 74.
    Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy. 2009;29(7):800–11.  https://doi.org/10.1592/phco.29.7.800.CrossRefPubMedGoogle Scholar
  75. 75.
    Orsi A, Pharm D, Sherman O, Pharm D, Woldeselassie Z, Pharm D. Simvastatin-associated memory loss. Pharmacotherapy. 2001;21(6):767–9.CrossRefGoogle Scholar
  76. 76.
    Wagstaff LR, Mitton MW, Arvik BML, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003;23(7):871–80.  https://doi.org/10.1592/phco.23.7.871.32720.CrossRefPubMedGoogle Scholar
  77. 77.
    E. Z, G. M, J.M. R. Association between statin use and Alzheimer’s disease. Neuroepidemiology. 2004;23(1–2):94–8.  https://doi.org/10.1159/000073981.CrossRefGoogle Scholar
  78. 78.
    Zandi PP, Sparks DL, Khachaturian AS, et al. Do statins reduce risk of incident dementia and Alzheimer disease? Arch Gen Psychiatry. 2005;62:217–24.CrossRefGoogle Scholar
  79. 79.
    Richardson K, Schoen M, French B, Umscheid CA, Mitchell MD. Review statins and cognitive function. Ann Intern. 2013;159:688–97.CrossRefGoogle Scholar
  80. 80.
    Kelley BJ, Glasser S. Cognitive effects of statin medications. CNS Drugs. 2014;28(5):411–9.  https://doi.org/10.1007/s40263-014-0147-5.CrossRefPubMedGoogle Scholar
  81. 81.
    Ott BR, Daiello LA, Dahabreh IJ, et al. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med. 2014;30(3):348–58.  https://doi.org/10.1007/s11606-014-3115-3.CrossRefGoogle Scholar
  82. 82.
    Steenland K, Zhao L, Goldstein FC, Levey AI. Statins and cognitive decline in older adults with normal cognition or mild cognitive impairment.  https://doi.org/10.1111/jgs.12414 CrossRefGoogle Scholar
  83. 83.
    Giannopoulos S, Katsanos AH, Kosmidou M, Tsivgoulis G. Statins and vascular dementia: a review. J Alzheimer’s Dis. 2014;42:315–20.  https://doi.org/10.3233/JAD-132366.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Internal Medicine, Section on Gerontology & Geriatric MedicineWake Forest School of MedicineWinston-SalemUSA

Personalised recommendations